Supplementary Figure 2 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 2 details PD-L1 expression is not observably altered following REG exposure.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4412843807
